Edwards Lifesciences
edwards.comTotal trials
126
Active
44
Phase 3
0
Total enrollment
42,273
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 1 of 1 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Optimal Medical Therapy | — | — | — | — | — | 2 |
Next readouts
- 2025-12-05
- 2027-12-31
Top conditions
- Aortic Valve Stenosis15
- Aortic Stenosis14
- Mitral Regurgitation12
- Mitral Valve Insufficiency11
- Heart Failure10
- Aortic Valve Disease8
- Cardiovascular Diseases8
- Mitral Valve Regurgitation8
Frequently asked questions about Edwards Lifesciences
- How many clinical trials does Edwards Lifesciences have on ClinicalTrials.gov?
- Edwards Lifesciences is listed as the lead sponsor on 126 clinical trials in ClinicalTrials.gov, 44 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Edwards Lifesciences's trials are in Phase 3?
- 0 of Edwards Lifesciences's trials are in Phase 3, spread across 1 active drug program.
- What therapeutic areas does Edwards Lifesciences focus on?
- Edwards Lifesciences's most-studied conditions on ClinicalTrials.gov are Aortic Valve Stenosis, Aortic Stenosis, Mitral Regurgitation, Mitral Valve Insufficiency, Heart Failure.
- When are Edwards Lifesciences's next clinical trial readouts?
- Edwards Lifesciences has 2 upcoming primary-completion readouts tracked here; the soonest is “TRISCEND II Pivotal Trial”, expected around 2025-12-05.